Bioelectronics Corp (BIEL)

[GetSeriousOK]

this MB is maddening. There is potential for actual discussion here, but it ends at "potential."

What do YOU think Staelin is talking about when he says they've developed a device with 50% more power that needs a new 510(k) application?

And why do YOU think they let the patents expire? I keep coming back to the occam's razor explanation, which I believe is: Whelan simply didn't know that patents need to be maintained, and the USPTO mail went to... the mother?

The obstacle couldn't have been money -- granted, the cost would have been about $30,000 for all the patents, but in mid-2021 they had money, or so they projected -- and Staelin would certainly have coughed up $30,000 for patent maintenance if money was the problem. He has skin in this game.

Losing the patents seems folly, to put it mildly. I don't think the Export-Import Bank will call in that loan and seize the collateral, but a prospective QUALITY future funding source won't be happy about investing in a biotech that has no patent-protected IP. Toxic lenders won't care, but the saving grace for this company is that they've somehow avoided the toxic lenders. If BIEL borrows from toxic lenders, look out below -- they will require a reverse split and then they'll send this ticker into a death spiral.

As for the defense that a new patent for "RecoveryRxtra" is pending, making the old patents obsolete.... Your thoughts?

Because I think we've established that there is no existing clinical data for the new RecoveryRxtra, and Ilfeld and Stanford aren't using a new higher-power device. It seems contradictory to me that a new patent is coming, implying a significant change that's more than a design change, but the FDA will still clear the device without new clinical data.